HepatologyVolume 38, Issue 2 p. 530-531 CorrespondenceFree Access Cytokine network during NASH and possible treatment selection Zhiping Li M.D., Zhiping Li M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorShiqi Yang M.D., Shiqi Yang M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorHuizhi Lin M.D., Huizhi Lin M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorJiawen Huang M.D., Jiawen Huang M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorPaul A. Watkins M.D., Paul A. Watkins M.D. The Johns Hopkins University, Baltimore, MD Kennedy Krieger Institute, Baltimore, MDSearch for more papers by this authorAnn B. Moser M.D., Ann B. Moser M.D. The Johns Hopkins University, Baltimore, MD Kennedy Krieger Institute, Baltimore, MDSearch for more papers by this authorClaudio DeSimone M.D., Claudio DeSimone M.D. University of L'Aquila, L'Aquila, ItalySearch for more papers by this authorXiao-yu Song M.D., Xiao-yu Song M.D. Centocor, Malvern, PASearch for more papers by this authorAnna Mae Diehl M.D., Anna Mae Diehl M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this author Zhiping Li M.D., Zhiping Li M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorShiqi Yang M.D., Shiqi Yang M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorHuizhi Lin M.D., Huizhi Lin M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorJiawen Huang M.D., Jiawen Huang M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this authorPaul A. Watkins M.D., Paul A. Watkins M.D. The Johns Hopkins University, Baltimore, MD Kennedy Krieger Institute, Baltimore, MDSearch for more papers by this authorAnn B. Moser M.D., Ann B. Moser M.D. The Johns Hopkins University, Baltimore, MD Kennedy Krieger Institute, Baltimore, MDSearch for more papers by this authorClaudio DeSimone M.D., Claudio DeSimone M.D. University of L'Aquila, L'Aquila, ItalySearch for more papers by this authorXiao-yu Song M.D., Xiao-yu Song M.D. Centocor, Malvern, PASearch for more papers by this authorAnna Mae Diehl M.D., Anna Mae Diehl M.D. The Johns Hopkins University, Baltimore, MDSearch for more papers by this author First published: 31 January 2007 https://doi.org/10.1002/hep.510380233AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098– 1104. 2 Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1393– 1395. 3 Kern PA, Saghizaheh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111– 2119. 4 Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158– 1163. 5 Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206– 211. 6 Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274– 280. 7 Loguercio C, DeSimone T, Federico A, Terracciano F, Tuccillo C, DiChicco M, Carteni M. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144– 2146. Volume38, Issue2August 2003Pages 530-531 ReferencesRelatedInformation